跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 17 条关于
“METex14”
全部
17
临床试验
7
药物
1
机构
0
资讯
9
去年
FDA Approves FoundationOne Liquid CDx as Companion Diagnostic for Tepotinib in METex14-Skipping NSCLC
3个月前
FDA Approves FoundationOne CDx as Companion Diagnostic for Tepotinib in MET Exon 14-Positive NSCLC
去年
AbbVie's Telisotuzumab Vedotin Shows Promise in c-Met Overexpressing NSCLC
去年
HUTCHMED Presents Clinical Data for Multiple Cancer Therapies at Major Oncology Conferences
4个月前
Apollomics Advances c-MET Inhibitor Vebreltinib Toward FDA Submission Following Strategic Turnaround
去年
Merus Advances Petosemtamab and Zenocutuzumab in Phase III Trials for Head and Neck Cancer and NRG1+ Cancers
去年
Savolitinib Plus TAGRISSO® Shows 56% Response Rate in MET-High Lung Cancer, HUTCHMED Reports
去年
MSK Researchers Spearhead Advances in Cancer Treatment, Leading to 11 FDA Approvals in 2024
11个月前
METTL14 Emerges as Key Regulator of Tumor Immunity and Immunotherapy Response